National Research Action Plan on Long COVID
The Research Plan provides the first U.S. government-wide national research agenda focused on advancing prevention, diagnosis, treatment, and provision of services and supports for individuals and families experiencing Long COVID. The reports represent the federal government’s response to ensure the acceleration of scientific progress and to provide individuals with Long COVID with the support and services they need. They affirm the U.S. government’s commitment to addressing the impacts of Long COVID with federal government resources, in collaboration with the private sector, and improving our Nation’s health and well-being.
Services and Supports for Longer-Term Impacts of COVID-19
The Services Report outlines federal services and mechanisms of support available to the public in addressing the longer-term effects of COVID-19. The reports represent the federal government’s response to ensure the acceleration of scientific progress and to provide individuals with Long COVID with the support and services they need. They affirm the U.S. government’s commitment to addressing the impacts of Long COVID with federal government resources, in collaboration with the private sector, and improving our Nation’s health and well-being.
Understanding the Public Health Workforce’s COVID-19 Mental Health Challenges
The recently released Morbidity and Mortality Weekly Report (MMWR), Symptoms of Depression, Anxiety, Post-traumatic Stress Disorder and Suicidal Ideation Among State, Tribal, Local and Territorial Public Health Workers During the COVID-19 Pandemic, and the Public Health Workforce Interests and Needs Survey (PH WINS) highlight the negative mental health consequences reported by the public health workforce as a result of the prolonged and ongoing COVID-19 pandemic, the public health response and the unprecedented vaccination campaign.
Health Worker Burnout
On May 23, United States Surgeon General Dr. Vivek Murthy issued a new advisory, the Surgeon General’s Advisory Addressing Health Worker Burnout, highlighting the urgent need to address the health worker burnout crisis across the country. This advisory details recommendations that different stakeholders can take to prevent burnout, improve health worker well-being, and strengthen the Nation’s public health infrastructure.
COVID-19 Therapeutics Thresholds, Orders, and Replenishment by Jurisdiction
On April 25, 2022, the distribution process for COVID-19 therapeutics to state and territorial health departments transitioned from the previous allocation process to one that more closely aligns with the allocation and ordering process for vaccines.
CDC Resources: Neurology
SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Centers for Disease Control and Prevention (CDC). These resources are categorized as Neurology
NIH Resource: Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
Ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor and a P-glycoprotein inhibitor, is coadministered with nirmatrelvir to increase the blood concentration of nirmatrelvir, thereby making it effective against SARS-CoV-2. Ritonavir may also increase blood concentrations of certain concomitant medications. Because ritonavir-boosted nirmatrelvir (Paxlovid) is the only highly effective oral antiviral for the treatment of COVID-19, drug interactions that can be safely managed should not preclude the use of this medication.
FDA Updates Sotrovimab Emergency Use Authorization
The Centers for Disease Control and Prevention (CDC) Nowcast data from April 5, 2022, estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50% in all Health and Human Services (HHS) U.S. regions. Data included in the health care provider fact sheet show the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant. Due to these data, sotrovimab is not authorized in any U.S. state or territory at this time.
New Paxlovid Dose Pack Authorized by FDA
On April 14, 2022, the FDA revised the Emergency Use Authorization (EUA) for the COVID-19 oral antiviral therapeutic Paxlovid to authorize an additional dose pack presentation with appropriate dosing for patients with moderate renal impairment within the scope of the EUA. As a result, Paxlovid will soon be available in two package presentations.
NIH Resource: Study Looks for Long COVID Risk Factors
In a study supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Center for Advancing Translational Sciences, and the National Institute on Drug Abuse, researchers enrolled 209 people ages 18 to 89 who had laboratory-confirmed SARS-CoV-2 infections.
The Society of Critical Care Medicine’s (SCCM) COVID-19 Rapid Resource Center gives you access to the latest education.
Looking for more: